Skip to main content

Table 2 Two-sided Fisher's exact tests for association of clinical variables and TIL-signature status with probability of pathological complete response (pCR) in the EORTC cohort

From: Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer

 

Total (n= 111)

FEC treated (n= 54)

TET treated (n= 57)

 

OR (95% CI)

Pvalue

OR (95% CI)

Pvalue

OR (95% CI)

Pvalue

Size T3 vs T1/T2

0.39 (0.17-0.89)

0.0292

0.60 (0.19-1.87)

0.4103

0.25 (0.19-1.87)

0.0278

Grade 3 vs 1/2

2.80 (1.19-6.61)

0.0226

2.35 (0.73-7.56)

0.1684

2.00 (0.58-6.86)

0.3681

Node 1 vs 0a

0.82 (0.38-1.78)

0.6927

1.05 (0.34-3.24)

1.0000

0.65 (0.22-1.92)

0.5823

Age ≥50 vs <50

0.89 (0.42-1.89)

0.8913

1.29 (0.43-3.82)

0.7827

0.62 (0.22-1.77)

0.4311

Her2 A vs Nb

1.21 (0.52-2.81)

0.6722

2.03 (0.53-7.72)

0.3243

0.81 (0.27-2.46)

0.7824

TET vs FEC

1.22 (0.57-2.59)

0.7022

NA

NA

NA

NA

TIL high vs low

6.33 (2.49-16.08)

<0.0001

6.48 (1.82-23.10)

0.0035

6.84 (1.65-28.39)

0.0059

  1. a1, lymph node positive; 0, lymph node negative. bA, amplified; N, not amplified.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us